Research Background

As long‑term side effects increase following treatment for cancer and other diseases, female infertility has become a prominent concern. Ovarian tissue cryopreservation (OTC) is a technique that freezes ovarian tissue, including immature oocytes, for potential future re‑implantation. This study aims to systematically collect the tissues and associated data from patients undergoing OTC.

Study Design

Participants are females aged 4 to 35 years who elect OTC prior to cancer therapy. Up to 20 % of the harvested tissue will be allocated for research, with the remainder reserved for clinical re‑implantation. Annual questionnaires will be administered for 30 years, and clinical records, laboratory and imaging results will be coded and stored longitudinally.

Expected Impact

By capturing natural history information on tissue and clinical data, the survival and functional recovery mechanisms of ovarian tissue can be quantified. This will provide essential evidence for developing adjunctive therapeutics or regenerative‑medicine approaches to improve OTC success rates. Long‑term follow‑up will also generate empirical evidence on adverse events and regenerative efficacy.

Industry and Market Significance

A biorepository can serve as a critical source of raw material for biotech companies developing ovarian‑tissue‑based therapeutics (e.g., ovarian‑derived stem cells, regenerative medicines). Although commercial OTC‑related products are currently limited, an expanded database is likely to stimulate partnerships and licensing transactions. In the long term, it can fuel growth in the female infertility treatment market, which is valued at several billion dollars.

Data Sharing and Regulatory Outlook

Because the database is a public resource led by the NIH, it is readily accessible to academia and industry, enhancing research transparency and reproducibility. In the future, regulatory agencies such as the FDA and EMA may rely on such long‑term data as critical evidence for safety and efficacy assessments when approving tissue‑based therapeutics.